ArticleCommunications biology2026
Resveratrol offers therapeutic potential in obesity-related osteoarthritis by targeting ferroptosis via G3BP1-SGs/mTOR modulation.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The increased ferroptosis by obesity contributes to the progression of osteoarthritis (OA). Resveratrol has protective effects against obesity-related OA. However, the underlying mechanisms remain unclear. Here, we investigated the mechanism of resveratrol against obesity-related OA using male C57BL/6 mice and chondrocyte models. The results demonstrated that high-fat diet (HFD) and IL-1β exacerbated cartilage damage in mice and chondrocytes, accompanied by worsening indicators of ferroptosis and upregulation of Ras-GTPase-activating protein binding protein 1 (G3BP1) expression and stress granules (SGs) assembly, which responds to environmental stressors such as obesity. Resveratrol alleviated these effects. After G3BP1 was silenced, resveratrol no longer had the effect of inhibiting ferroptosis and reducing cartilage degradation; while mTOR inhibition rescued ferroptosis-related protective proteins. This study suggests that resveratrol exerts protective effects against obesity-related OA, at least in part, by modulating ferroptosis-related changes in chondrocytes through the G3BP1-SGs/mTOR pathway. These findings provide new insights into OA pathogenesis and highlight resveratrol as a promising therapeutic strategy for obesity-related OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.